ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

Capital will Support Continued Development of First-in-Class GPR35 Inhibitor Program for the Treatment of Ulcerative Colitis Utilizing Biomarker-Driven, Precision Medicine Strategy

OXFORD, United Kingdom, April 15, 2025 /PRNewswire/ -- ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today announced the closing of a bridge round of financing, which included a strategic investment from AbbVie Ventures, along with support from an existing investor Canaan and new investor Mayewell Capital. The funds will support the continued development of the company's first-in-class GPR35 inhibitor program, which is currently advancing through preclinical development, including investigational new drug (IND)-enabling studies designed to pave the way for initiation of first-in-human clinical trials.

"Despite recent advances, patients with Inflammatory Bowel Disease (IBD) are still suffering," said Timothy Radstake, M.D., Ph.D., vice president and global head of immunology discovery research, AbbVie. "Abbvie Ventures invests in opportunities to deliver future pipeline substrates with the potential to break through the therapeutic ceiling in diseases like IBD. We are excited to partner with ThirtyFiveBio to explore the potential therapeutic benefit of targeting GPR35 for the treatment of IBD."

GPR35 is a genetically validated target in inflammatory bowel disease, including ulcerative colitis. ThirtyFiveBio and its collaborators have shown that gain-of-function variants of GPR35 are associated with disease. Using human biology, patient data, and patient-derived assays, the company is also demonstrating that GPR35 inhibition is a modality with the potential to resolve underlying disease by preventing epithelial cell damage and dysfunction in the gut wall rather than symptomatic inflammation. In this way, GPR35 inhibition can be considered an "epithelial shield." As such, GPR35 is a differentiated and orthogonal approach to direct anti-inflammatory modalities with the potential to deliver a novel mechanism of treatment that will improve disease resolution and remission rates.

Supported by the company's work with several world-leading academic GPR35 and clinical colitis specialists, ThirtyFiveBio is uniquely pursuing antagonism of GPR35 in patients with ulcerative colitis with first-in-class small molecule inhibitors.  The company is leveraging informatic analysis of patient tissue to identify subsets of patients who are enriched for GPR35 inhibitor responsiveness based on their unique genetic signatures and biology.  The resulting biomarkers for GPR35 inhibitor responsiveness, once validated, will provide the means for precision patient selection in planned clinical trials.

"We believe that we occupy a unique and advantageous position within the GPR35-targeted therapeutic space based on our deep understanding of GPR35 biology and how it contributes to GI-related diseases, including colitis and gut cancers. Our discussions with the teams at AbbVie Ventures, as well as Canaan and Mayewell Capital, generated an appreciation for both our competitive differentiation and scientific thought leadership," said James Westcott, Ph.D., chief executive officer of ThirtyFiveBio. "The support from these premier investors offers great validation for the work that our team has already undertaken in this area, as well as the broad therapeutic potential of the platform moving forward. We are eager to continue to advance the program toward the clinic with the goal of establishing proof-of-concept in patients and will be looking for further partners to come on board to support these aims through a syndicated Series A later this year." 

About ThirtyFiveBio

ThirtyFiveBio Limited is a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease. The company has built scientific thought leadership in the biology of GPR35 and the role that it plays in GI disease, including digestive tract colitis and cancers. ThirtyFiveBio has leveraged its fully enabled drug discovery platform to identify multiple unique families of first-in-class small-molecule GPR35 inhibitors with priority molecules in development candidate nomination studies. Created by Molecule to Medicine (MTM), a unique drug discovery and development ecosystem, and Canaan Partners, the company has raised nearly $25 million in financing to date. ThirtyFiveBio is headquartered on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit: www.thirtyfivebio.com.  To learn more about MTM please visit: www.moleculetomedicine.com.

Contacts:
ThirtyFiveBio
James Westcott
Chief Executive Officer
P: +44 (0)1235 644980
[email protected]

Vida Strategic Partners (on behalf of ThirtyFiveBio)
Tim Brons (Media)
415-675-7402
[email protected]

SOURCE ThirtyFiveBio